News

Pursuant to the terms of contract, Bristol-Myers will implement Mobile Intelligence, Cegedim’s customer relationship management (CRM) solution, to its neurosciences sales team. The new agreement also includes the

Phadia, a developer and marketer of blood test systems, has launched the Phadia Immunology Reference Laboratory, or PiRL, the result of a research collaboration between the company and

The collaboration focuses on validating certain gene targets using small interfering RNA (siRNA) provided by Bristol-Myers Squibb and employing Tekmira’s stable nucleic-acid lipid particle (SNALP) formulations to deliver

Mr Enright has served as president of the Canadian Investor Relations Institute since November 2008. In September 2008, Mr Enright retired from his position as president and CEO

MDRNA, a biotechnology company, has reported a net loss of $12.30m or $0.39 per share, for the fourth quarter of 2008, compared to a net loss of $12.01m

“Response Genetics continues to make great strides as a company. During this past year, we successfully launched our ResponseDX: Lung and ResponseDX: Colon genetic tests; brought the promise

The new drug application (NDA) of T-614 was submitted to the Japanese Ministry of Health, Labour and Welfare by the companies on September 24, 2003. Subsequent interviews with

According to Digirad, the Cardius X-Act is a rapid cardiac Single photon emission computed tomography (SPECT)/VCT imaging system that features a low-dose volume-computed tomography (VCT) attenuation correction system

Results of Operations Year ended December 31, 2008 compared to year ended December 31, 2007 Cost of Revenues and Gross Profit Cost of revenue for 2008, was $2,879,839